Tempus ECG-Low EF vs AVIEW Lung Nodule CAD
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A specializes in detecting signs of low left ventricular ejection fraction from ECGs, focusing on early heart failure risk assessment. Tool B, on the other hand, analyzes chest CT scans for pulmonary nodules, emphysema, and coronary artery calcification, offering a broader cardiopulmonary assessment. While both tools have applications within cardiology, their differing input modalities and primary diagnostic targets make them suitable for distinct clinical use cases.
Choose Tempus ECG-Low EF if…
Choose Tempus ECG-Low EF if your primary objective is to leverage AI for early identification of patients aged 40 or older who may be at risk of heart failure, based on routine 12-lead ECG recordings. This tool is ideal for integrating into cardiology, emergency medicine, or internal medicine workflows to efficiently flag individuals for further cardiac evaluation when a low left ventricular ejection fraction is suspected.
View Tempus ECG-Low EF →Choose AVIEW Lung Nodule CAD if…
Choose AVIEW Lung Nodule CAD if your clinical practice requires advanced AI assistance for comprehensive pulmonary nodule detection, characterization, and follow-up on chest CT scans. This solution is particularly well-suited for radiology and pulmonology departments aiming to enhance lung cancer screening programs while simultaneously assessing for emphysema and coronary artery calcification from the same imaging study.
View AVIEW Lung Nodule CAD →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-Low EF | AVIEW Lung Nodule CAD |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software, integrated into healthcare facility workflows | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | 1 AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-Low EF | AVIEW Lung Nodule CAD |
|---|---|---|
| Tool Name | Tempus ECG-Low EF | AVIEW Lung Nodule CAD |
| Company | Tempus AI | Coreline Soft Co. |
| Primary Function | Analyzes 12-lead ECG recordings to detect signs associated with low left ventricular ejection fraction (LVEF u226440%) in patients 40 years or older at risk of heart failure. | Assists radiologists in detecting and analyzing pulmonary nodules on chest CT scans, and offers comprehensive screening for lung cancer, COPD, and coronary artery calcification. |
| Target Medical Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Pulmonology, Radiology |
| Input Data Type | Resting, non-ambulatory 12-lead ECG recordings | Chest CT scans |
| Key AI Analysis/Output | Binary output (Low LVEF Detected / Not Detected) based on ECG analysis. | AI-based pulmonary nodule detection (3-20 mm), nodule classification (solid, part-solid, non-solid), 3D nodule size and volume quantification, automatic report generation based on Lung-RADS classification. |
| Additional Capabilities | Aids in identifying patients 40+ years at risk of heart failure. | Nodule matching and volume doubling time (VDT) calculation for follow-up comparisons, simultaneous analysis of lung nodules, emphysema, and coronary artery calcification (Big 3), quantitative emphysema analysis, Coronary Artery Calcification (CAC) scoring. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-Low EF and AVIEW Lung Nodule CAD.
Loading videos…
Videos need JavaScript to load. Search YouTube directly →
Frequently Asked Questions
Tempus ECG-Low EF is designed for patients 40 years or older at risk of heart failure, using ECGs to detect signs of low LVEF. AVIEW Lung Nodule CAD assists radiologists in analyzing chest CT scans for pulmonary nodules, emphysema, and coronary artery calcification, relevant for lung cancer screening and broader cardiopulmonary assessment.
Tempus ECG-Low EF provides a binary output from ECG analysis to aid in further evaluation for low LVEF, integrating into general healthcare facility workflows. AVIEW Lung Nodule CAD assists radiologists by providing detailed analysis, quantification, and automatic report generation for CT scans, potentially streamlining the interpretation of complex imaging studies.
Tempus ECG-Low EF offers a binary 'Low LVEF Detected / Not Detected' output to prompt further evaluation for heart failure risk. AVIEW Lung Nodule CAD provides comprehensive data including nodule classification, 3D quantification, Lung-RADS scoring, volume doubling time, quantitative emphysema analysis, and coronary artery calcification scores, offering multi-faceted insights for diagnosis and follow-up.
Tempus ECG-Low EF provides a straightforward binary output, suggesting a potentially lower learning curve for interpretation. AVIEW Lung Nodule CAD offers a more comprehensive suite of quantitative analyses and classifications (e.g., Lung-RADS, VDT, CAC scores), which may require more familiarity for optimal utilization by radiologists and pulmonologists.
Tempus ECG-Low EF is integrated into healthcare facility workflows, implying a need for standardized ECG acquisition and processing across sites. AVIEW Lung Nodule CAD, by assisting radiologists with complex CT analysis, would require consistent training and potentially workflow adjustments for radiology departments across multiple facilities to ensure uniform application and interpretation.
The provided descriptions do not explicitly detail audit trail capabilities or transparency features for either tool. Physicians would need to inquire with the vendors about how AI-generated findings are logged and traceable within their systems to support clinical governance.